Endocrinology Therapeutics
1. Actos patent expiration
Treatment: Method of reducing side effects of active components admin to a diabetic by admin a chemical compound having formula (incl pioglitazone) in combination with an insulin secretion enhancer; A method of ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303640 | TAKEDA PHARMS USA | Pharmaceutical composition |
Aug, 2016
(9 years ago) | |
| US6150384 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6166042 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6150383 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US5965584 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6271243 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6329404 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6172090 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6211205 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6166043 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
Drugs and Companies using PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 July, 1999
Dosage: TABLET
How can I launch a generic of ACTOS before it's drug patent expiration?
More Information on Dosage
ACTOS family patents
2. Avandia patent expiration
Treatment: Method of treatment of type ii diabetes; Use of avandia as monotherapy, in combination with metformin, and in combination with sulfonylureas to improve glycemic control in patients with type 2 diabete...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6288095 (Pediatric) | WOODWARD | Compounds |
Aug, 2017
(8 years ago) | |
|
US5741803 (Pediatric) | WOODWARD | Substituted thiazolidinedionle derivatives |
Oct, 2015
(10 years ago) | |
| US6288095 | WOODWARD | Compounds |
Feb, 2017
(8 years ago) | |
| US5741803 | WOODWARD | Substituted thiazolidinedionle derivatives |
Apr, 2015
(10 years ago) | |
| US7358366 | WOODWARD | Thiazolidinedione derivative and its use as antidiabetic |
Apr, 2020
(5 years ago) | |
|
US7358366 (Pediatric) | WOODWARD | Thiazolidinedione derivative and its use as antidiabetic |
Oct, 2020
(5 years ago) | |
Drugs and Companies using ROSIGLITAZONE MALEATE ingredient
Market Authorisation Date: 25 May, 1999
Dosage: TABLET
How can I launch a generic of AVANDIA before it's drug patent expiration?
More Information on Dosage
AVANDIA family patents
3. Brenzavvy patent
expiration
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8802637 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(2 years from now) | |
| US7838499 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Jan, 2029
(3 years from now) | |
| US8987323 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
May, 2032
(6 years from now) | |
| US10981942 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jun, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533032 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jul, 2031
(5 years from now) | |
| US8106021 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 20 January, 2027
Market Authorisation Date: 20 January, 2023
Dosage: TABLET
More Information on Dosage
BRENZAVVY family patents
4. Brynovin patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12295953 | AZURITY | Oral gliptin compositions and method for preparation thereof |
Oct, 2040
(14 years from now) | |
| US11944621 | AZURITY | Oral gliptin compositions and method for preparation thereof |
Oct, 2040
(14 years from now) | |
Drugs and Companies using SITAGLIPTIN HYDROCHLORIDE ingredient
Market Authorisation Date: 16 January, 2025
Dosage: SOLUTION
More Information on Dosage
BRYNOVIN family patents
5. Crenessity patent expiration
Treatment: Adjunctive treatment of classic congenital adrenal hyperplasia (cah)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12128033 | NEUROCRINE | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine |
Jun, 2041
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10905690 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11311544 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11730739 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2029 |
| Orphan Drug Exclusivity(ODE-503) | Dec 13, 2031 |
Drugs and Companies using CRINECERFONT ingredient
NCE-1 date: 13 December, 2028
Market Authorisation Date: 13 December, 2024
Dosage: CAPSULE; SOLUTION
More Information on Dosage
CRENESSITY family patents
6. Hectorol patent expiration
Treatment: Reduction of elevated ipth levels in the mgt of secondary hyperparathyroidism in patients undergong chronic renal dialysis
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6903083 | SANOFI | Stabilized hydroxyvitamin D |
Jul, 2021
(4 years ago) | |
| US5602116 | SANOFI | Method for treating and preventing secondary hyperparathyroidism |
Feb, 2014
(11 years ago) | |
| US7148211 | SANOFI | Formulation for lipophilic agents |
Sep, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-14) | Jun 11, 2028 |
Drugs and Companies using DOXERCALCIFEROL ingredient
Market Authorisation Date: 23 April, 2004
Dosage: CAPSULE; INJECTABLE
How can I launch a generic of HECTOROL before it's drug patent expiration?
More Information on Dosage
HECTOROL family patents
7. Imcivree patent expiration
Treatment: NA
IMCIVREE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9458195 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(1 year, 9 months from now) | |
| US8039435 | RHYTHM | Melanocortin receptor ligands |
Aug, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129869 | RHYTHM | Pharmaceutical compositions |
Jul, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-892) | Jun 16, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2025 |
| Orphan Drug Exclusivity(ODE-336) | Nov 25, 2027 |
| New Patient Population(NPP) | Dec 20, 2027 |
| Orphan Drug Exclusivity(ODE-402) | Jun 16, 2029 |
| Orphan Drug Exclusivity(ODE-508) | Dec 20, 2031 |
| Orphan Drug Exclusivity(ODE-509) | Dec 20, 2031 |
Drugs and Companies using SETMELANOTIDE ACETATE ingredient
NCE-1 date: 25 November, 2024
Market Authorisation Date: 25 November, 2020
Dosage: SOLUTION
More Information on Dosage
IMCIVREE family patents
8. Inpefa patent expiration
Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476413 | LEXICON PHARMS INC | Sulfanyl-tetrahydropyran-based compounds and methods of their use |
May, 2028
(2 years from now) | |
| US7781577 | LEXICON PHARMS INC | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
May, 2028
(2 years from now) | |
| US8217156 | LEXICON PHARMS INC | Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use |
Oct, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2028 |
Drugs and Companies using SOTAGLIFLOZIN ingredient
NCE-1 date: 27 May, 2027
Market Authorisation Date: 26 May, 2023
Dosage: TABLET
More Information on Dosage
INPEFA family patents
9. Invokana patent expiration
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascu...
INVOKANA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(1 year, 10 months from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(3 years from now) | |
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(8 months ago) | |
| US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(5 years from now) | |
|
US10617668 (Pediatric) | JANSSEN PHARMS | Pharmaceutical formulations |
Nov, 2031
(5 years from now) | |
|
US7943582 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Aug, 2029
(3 years from now) | |
|
US7943788 (Pediatric) | JANSSEN PHARMS | Glucopyranoside compound |
Jan, 2028
(2 years from now) | |
|
US8222219 (Pediatric) | JANSSEN PHARMS | Glucopyranoside compound |
Oct, 2025
(2 months ago) | |
|
US8513202 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Jun, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Indication(I-809) | Sep 27, 2022 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 29 March, 2013
Dosage: TABLET
How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage
INVOKANA family patents
10. Isturisa patent expiration
Treatment: Cushing's disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(7 months from now) | |
| US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(5 years from now) | |
| US8314097 | RECORDATI RARE | Organic compounds |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(9 years from now) | |
| US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(5 years from now) | |
| US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2025 |
| Orphan Drug Exclusivity(ODE-286) | Mar 06, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 06 March, 2024
Market Authorisation Date: 06 March, 2020
Dosage: TABLET
More Information on Dosage
ISTURISA family patents
11. Januvia patent expiration
Treatment: Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin.; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor ...
JANUVIA's oppositions filed in EPO
JANUVIA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7459428 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US7078381 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US6890898 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(3 years ago) | |
| US6303661 | MERCK SHARP DOHME | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(8 years ago) | |
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(3 years ago) | |
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(2 years ago) | |
|
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(2 years ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 16 October, 2006
Dosage: TABLET
How can I launch a generic of JANUVIA before it's drug patent expiration?
More Information on Dosage
JANUVIA family patents
12. Jardiance patent expiration
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment...
JARDIANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(2 years from now) | |
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(4 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(8 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(8 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
| US12115179 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Feb, 2030
(4 years from now) | |
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(3 years from now) | |
| US12433906 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
| US12263153 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
| US12427162 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
| US11666590 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
| US11813275 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(3 years from now) | |
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(1 year, 9 months from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(8 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(8 years from now) | |
|
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(4 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(8 years from now) | |
|
US11813275 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
|
US11833166 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
|
US12115179 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Aug, 2030
(4 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(8 years from now) | |
|
US12433906 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Dosage: TABLET
How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage
JARDIANCE family patents
13. Kerendia patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE49826 | BAYER HLTHCARE | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
Jul, 2035
(9 years from now) | |
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-279) | Sep 01, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 09, 2026 |
| New Indication(I-970) | Jul 11, 2028 |
| New Strength(NS) | Jul 11, 2028 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 09 July, 2025
Market Authorisation Date: 09 July, 2021
Dosage: TABLET
More Information on Dosage
KERENDIA family patents
14. Macrilen patent expiration
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6861409 | NOVO | Growth hormone secretagogues |
Aug, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8192719 | NOVO | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Oct, 2027
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2022 |
| Orphan Drug Exclusivity(ODE-170) | Dec 20, 2024 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: 20 December, 2021
Market Authorisation Date: 20 December, 2017
Dosage: FOR SOLUTION
More Information on Dosage
MACRILEN family patents
15. Mounjaro patent expiration
Treatment: Treatment of type 2 diabetes by administering in 4 doses, at least 2 weeks apart, a gip:glp-1 peptide having a gip:glp-1 receptor agonist potency ratio in a range determined by a casein camp assay, wh...
MOUNJARO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(13 years from now) | |
| US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12295987 | ELI LILLY AND CO | Method of using a GIP/GLP1 co-agonist for diabetes |
Dec, 2041
(15 years from now) | |
| US12343382 | ELI LILLY AND CO | NA |
Jul, 2039
(13 years from now) | |
| US12453755 | ELI LILLY AND CO | NA |
Jun, 2039
(13 years from now) | |
| US12453756 | ELI LILLY AND CO | NA |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Dosage: SOLUTION
More Information on Dosage
MOUNJARO family patents
16. Mycapssa patent expiration
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term main...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11338011 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11141457 | CHIESI | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(14 years from now) | |
| US10695397 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US12251418 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US12246054 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US8535695 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US10238709 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11510963 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11857595 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11052126 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11890316 | CHIESI | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(14 years from now) | |
| US11986529 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US11969471 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US8329198 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US9265812 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US9566246 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 26, 2023 |
| Orphan Drug Exclusivity(ODE-474) | Jun 26, 2027 |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 26 June, 2020
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
MYCAPSSA family patents
17. Nesina patent expiration
Treatment: Methods of treating lipid metabolism and glycometabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer; Meth...
Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(2 years from now) | |
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6150383 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6303661 | TAKEDA PHARMS USA | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(8 years ago) | |
| US6303640 | TAKEDA PHARMS USA | Pharmaceutical composition |
Aug, 2016
(9 years ago) | |
| US6211205 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US7078381 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US7459428 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US6329404 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6890898 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Dec, 2025
(a month ago) | |
| US8697125 | TAKEDA PHARMS USA | Tablet preparation without causing a tableting trouble |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
| M(M-300) | Jul 27, 2026 |
Drugs and Companies using ALOGLIPTIN BENZOATE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Dosage: TABLET
How can I launch a generic of NESINA before it's drug patent expiration?
More Information on Dosage
NESINA family patents
18. Onglyza patent expiration
Treatment: Method for treating type ii diabetes by administering saxagliptin
ONGLYZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395767 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Feb, 2021
(4 years ago) | |
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(2 years ago) | |
| US7951400 | ASTRAZENECA AB | Coated tablet formulation and method |
Nov, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
| M(M-108) | Dec 16, 2014 |
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 31 July, 2009
Dosage: TABLET
How can I launch a generic of ONGLYZA before it's drug patent expiration?
More Information on Dosage
ONGLYZA family patents
19. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
Treatment: Method of treating type 2 diabetes mellitus; A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indica...
OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(2 months from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(2 years ago) | |
| US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US12295988 | NOVO | Semaglutide in medical therapy |
Oct, 2038
(12 years from now) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 months ago) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(10 days from now) | |
| US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(7 years from now) | |
| US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(10 days from now) | |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 months ago) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 months ago) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(10 days from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(6 months from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(6 months from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(10 days from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(6 months from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(10 days from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(10 days from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(6 months from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(1 year, 8 months from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(1 year, 1 month from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(6 months from now) | |
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(4 months ago) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Indication(I-961) | Jan 28, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage
OZEMPIC family patents
20. Palsonify patent expiration
Treatment: Treatment of adults with acromegaly who have hepatic impairment and an inadequate response to surgery and/or for whom surgery is not an option; Treatment of adults with acromegaly who had an inadequat...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11414397 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10597377 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10351547 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US9896432 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10464918 | CRINETICS | NA |
Jan, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12208092 | CRINETICS | NA |
Mar, 2044
(18 years from now) | |
| US11957674 | CRINETICS | NA |
Sep, 2041
(15 years from now) | |
| US11266641 | CRINETICS | NA |
Sep, 2041
(15 years from now) | |
| US10875839 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2030 |
Drugs and Companies using PALTUSOTINE HYDROCHLORIDE ingredient
NCE-1 date: 25 September, 2029
Market Authorisation Date: 25 September, 2025
Dosage: TABLET
More Information on Dosage
PALSONIFY family patents
21. Sensipar patent expiration
Treatment: Method of decreasing or reducing parathyroid hormone level; Method of modulating parathyroid hormone secretion; Method of treating hyperparathyroidism; Method of reducing serum ionized calcium level; ...
SENSIPAR's oppositions filed in EPO
SENSIPAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6031003 | AMGEN | Calcium receptor-active molecules |
Dec, 2016
(9 years ago) | |
| US6211244 | AMGEN | Calcium receptor-active compounds |
Oct, 2015
(10 years ago) | |
| US6011068 | AMGEN | Calcium receptor-active molecules |
Mar, 2018
(7 years ago) | |
| US6313146 | AMGEN | Calcium receptor-active molecules |
Dec, 2016
(9 years ago) | |
| US7829595 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(8 months from now) | |
| US9375405 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-634) | Feb 25, 2014 |
| M(M-101) | Feb 25, 2014 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2018 |
| Orphan Drug Exclusivity(ODE-8) | Feb 25, 2018 |
| M(M-200) | May 23, 2020 |
| Orphan Drug Exclusivity(ODE-78) | Nov 21, 2021 |
Drugs and Companies using CINACALCET HYDROCHLORIDE ingredient
Market Authorisation Date: 08 March, 2004
Dosage: TABLET
How can I launch a generic of SENSIPAR before it's drug patent expiration?
More Information on Dosage
SENSIPAR family patents
22. Signifor patent expiration
Treatment: NA
Can you believe SIGNIFOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8299209 | RECORDATI RARE | Pharmaceutical composition comprising cyclic somatostatin analogues |
Dec, 2025
(13 days ago) | |
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6225284 | RECORDATI RARE | Somatostatin peptides |
Jun, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE-34) | Dec 14, 2019 |
Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 14 December, 2012
Dosage: SOLUTION
More Information on Dosage
SIGNIFOR family patents
23. Somatuline Depot patent expiration
Treatment: Method of administering lanreotide acetate
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5595760 | IPSEN PHARMA | Sustained release of peptides from pharmaceutical compositions |
Mar, 2020
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2012 |
| New Dosing Schedule(D-131) | Mar 04, 2014 |
| Orphan Drug Exclusivity(ODE) | Aug 30, 2014 |
| New Indication(I-701) | Dec 19, 2017 |
| New Indication(I-754) | Sep 15, 2020 |
| Orphan Drug Exclusivity(ODE-82) | Dec 16, 2021 |
| Orphan Drug Exclusivity(ODE-156) | Sep 15, 2024 |
Drugs and Companies using LANREOTIDE ACETATE ingredient
NCE-1 date: 31 August, 2011
Market Authorisation Date: 30 August, 2007
Dosage: SOLUTION
More Information on Dosage
SOMATULINE DEPOT family patents
24. Starlix patent expiration
Treatment: Use as a blood glucose-lowering agent; Use for treatment of diabetes, particularly type 2 diabetes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6641841 | NOVARTIS | Tablet composition |
Nov, 2017
(8 years ago) | |
| US5463116 | NOVARTIS | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
Oct, 2012
(13 years ago) | |
| US5488150 | NOVARTIS | Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them |
Jan, 2013
(12 years ago) | |
| US6559188 | NOVARTIS | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
Sep, 2020
(5 years ago) | |
| US6844008 | NOVARTIS | Tablet composition |
Nov, 2017
(8 years ago) | |
| US6878749 | NOVARTIS | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
Sep, 2020
(5 years ago) | |
Drugs and Companies using NATEGLINIDE ingredient
Market Authorisation Date: 22 December, 2000
Dosage: TABLET
How can I launch a generic of STARLIX before it's drug patent expiration?
More Information on Dosage
STARLIX family patents
25. Symlin patent expiration
Treatment: Treatment of diabetes with an amylin agonist; Treatment of diabetes with an amylin agonist, including with insulin; Use of an amylin agonist to reduce gastric motility and treat post prandial hypergly...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5814600 | ASTRAZENECA AB | Method and composition for treatment of insulin requiring mammals |
Sep, 2015
(10 years ago) | |
| US5686411 | ASTRAZENECA AB | Amylin agonist peptides and uses therefor |
Mar, 2019
(6 years ago) | |
| US6608029 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Sep, 2013
(12 years ago) | |
| US6114304 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Sep, 2017
(8 years ago) | |
Drugs and Companies using PRAMLINTIDE ACETATE ingredient
Market Authorisation Date: 25 September, 2007
Dosage: INJECTABLE
More Information on Dosage
SYMLIN family patents
26. Tradjenta patent expiration
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); Method of treating type 2 diabetes mellitus by adm...
TRADJENTA's oppositions filed in EPO
TRADJENTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7459428 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(2 years ago) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(1 year, 3 months from now) | |
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(2 years ago) | |
| US6890898 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US7078381 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US9486526 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(3 years from now) | |
| US8853156 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Mar, 2031
(5 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(1 year, 3 months from now) | |
| US6303661 | BOEHRINGER INGELHEIM | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(8 years ago) | |
| US12364700 | BOEHRINGER INGELHEIM | NA |
Jun, 2037
(11 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(4 years from now) | |
| US11911388 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Apr, 2030
(4 years from now) | |
| US10034877 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(3 years from now) | |
| US12178819 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(1 year, 3 months from now) | |
| US11033552 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(1 year, 3 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(a month ago) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(2 months ago) | |
|
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(4 years from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(4 months from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(1 year, 9 months from now) | |
|
US8853156 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Sep, 2031
(5 years from now) | |
|
US10034877 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(4 years from now) | |
|
US9486526 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(4 years from now) | |
|
US11033552 (Pediatric) | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
Nov, 2027
(1 year, 9 months from now) | |
|
US12364700 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Dec, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-118) | Aug 13, 2015 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Dosage: TABLET
How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage
TRADJENTA family patents
27. Tymlos patent expiration
Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Use for detecting neutralizing antibodies; Treatment to increase bone density in men with osteoporosis at high ris...
TYMLOS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748382 | RADIUS | Method of drug delivery for bone anabolic protein |
Oct, 2027
(1 year, 8 months from now) | |
| US11680942 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog |
Jan, 2040
(14 years from now) | |
| US7803770 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(5 years from now) | |
| US11255842 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog |
Jan, 2040
(14 years from now) | |
| US11782041 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(12 years from now) | |
| USRE49444 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(5 years from now) | |
| US8148333 | RADIUS | Stable composition comprising a PTHrP analogue |
Nov, 2027
(1 year, 9 months from now) | |
| US11977067 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(12 years from now) | |
| US10996208 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| M(M-270) | Sep 20, 2024 |
| New Indication(I-907) | Dec 19, 2025 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Dosage: SOLUTION
How can I launch a generic of TYMLOS before it's drug patent expiration?
More Information on Dosage
TYMLOS family patents
28. Vaprisol patent expiration
Treatment: Method of using antagonist of arginine vasopressin (ava) v1a and v2 receptors for intravenous treatment of patients with hypervolemic hyponatremia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5723606 | CUMBERLAND | Condensed benzazepine derivative and pharmaceutical composition thereof |
Dec, 2019
(6 years ago) | |
Drugs and Companies using CONIVAPTAN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 December, 2005
Dosage: INJECTABLE
More Information on Dosage
VAPRISOL family patents
29. Veozah patent expiration
Treatment: Treatment of moderate to severe vasomotor symptoms due to menopause
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9422299 | ASTELLAS | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(8 years from now) | |
| US8871761 | ASTELLAS | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
Apr, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10836768 | ASTELLAS | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(8 years from now) | |
| US9987274 | ASTELLAS | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 12, 2028 |
Drugs and Companies using FEZOLINETANT ingredient
NCE-1 date: 13 May, 2027
Market Authorisation Date: 12 May, 2023
Dosage: TABLET
More Information on Dosage
VEOZAH family patents
30. Victoza patent expiration
Treatment: A method for improving glycemic control in adults with type 2 diabetes mellitus; Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults...
VICTOZA's oppositions filed in EPO
VICTOZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114833 | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6458924 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2017
(8 years ago) | |
|
USRE41956 (Pediatric) | NOVO NORDISK INC | Dose setting limiter |
Jul, 2021
(4 years ago) | |
| US7235627 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2017
(8 years ago) | |
| US6268343 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2017
(8 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(6 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(6 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(2 years ago) | |
|
US6268343 (Pediatric) | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Feb, 2023
(2 years ago) | |
|
US8579869 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(2 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(4 years ago) | |
| US8846618 | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Jun, 2022
(3 years ago) | |
|
US8846618 (Pediatric) | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Dec, 2022
(3 years ago) | |
| US9968659 | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jan, 2037
(11 years from now) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(6 years from now) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 months ago) | |
|
US7762994 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(1 year, 1 month ago) | |
|
US9265893 (Pediatric) | NOVO NORDISK INC | Injection button |
Mar, 2033
(7 years from now) | |
|
US8114833 (Pediatric) | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(a month from now) | |
|
US9968659 (Pediatric) | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jul, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| M(M-115) | Apr 06, 2015 |
| M(M-176) | Apr 22, 2019 |
| New Indication(I-750) | Aug 25, 2020 |
| New Patient Population(NPP) | Jun 17, 2022 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Dosage: SOLUTION
How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage
VICTOZA family patents
31. Voxzogo patent expiration
Treatment: Use to increase linear growth in pediatric patients with achondroplasia with open epiphyses
VOXZOGO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12233106 | BIOMARIN PHARM | C-type natriuretic peptide variants to treat skeletal dysplasia in children |
Jul, 2042
(16 years from now) | |
| US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(10 years from now) | |
| US11911446 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(10 years from now) | |
| US11590204 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(10 years from now) | |
| USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(4 years from now) | |
| US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 19, 2026 |
| Orphan Drug Exclusivity(ODE-387) | Nov 19, 2028 |
| Orphan Drug Exclusivity(ODE-449) | Oct 20, 2030 |
Drugs and Companies using VOSORITIDE ingredient
NCE-1 date: 19 November, 2025
Market Authorisation Date: 19 November, 2021
Dosage: POWDER
More Information on Dosage
VOXZOGO family patents
32. Welchol patent expiration
Treatment: Use as a bile acid sequestrant for lowering cholesterol; A method for reducing serum glucose levels in adults with type 2 diabetes mellitus; Use as a bile acid sequestrant
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5693675 | COSETTE | Alkylated amine polymers |
Dec, 2014
(11 years ago) | |
| US6784254 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US6433026 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US5607669 | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Jun, 2014
(11 years ago) | |
| US5679717 | COSETTE | Method for removing bile salts from a patient with alkylated amine polymers |
Apr, 2014
(11 years ago) | |
| US7229613 | COSETTE | Method for lowering serum glucose |
Apr, 2022
(3 years ago) | |
| US6066678 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US5919832 | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Apr, 2014
(11 years ago) | |
| US5917007 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US7101960 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
|
US5917007 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US5693675 (Pediatric) | COSETTE | Alkylated amine polymers |
Jun, 2015
(10 years ago) | |
|
US5679717 (Pediatric) | COSETTE | Method for removing bile salts from a patient with alkylated amine polymers |
Oct, 2014
(11 years ago) | |
|
US6066678 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US5607669 (Pediatric) | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Dec, 2014
(11 years ago) | |
|
US5919832 (Pediatric) | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Oct, 2014
(11 years ago) | |
|
US6433026 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US6784254 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US7101960 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US7229613 (Pediatric) | COSETTE | Method for lowering serum glucose |
Oct, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-608) | Oct 02, 2012 |
| Pediatric Exclusivity(PED) | Apr 02, 2013 |
| M(M-232) | Oct 20, 2024 |
Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient
Market Authorisation Date: 26 May, 2000
Dosage: CAPSULE; FOR SUSPENSION; TABLET; BAR, CHEWABLE
How can I launch a generic of WELCHOL before it's drug patent expiration?
More Information on Dosage
WELCHOL family patents
33. Yorvipath patent expiration
Treatment: Treatment of hypoparathyroidism in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906847 | ASCENDIS PHARMA BONE | Prodrug comprising a drug linker conjugate |
Apr, 2031
(5 years from now) | |
| US11890326 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11918628 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12453778 | ASCENDIS PHARMA BONE | NA |
Sep, 2037
(11 years from now) | |
| US12403182 | ASCENDIS PHARMA BONE | NA |
Nov, 2042
(16 years from now) | |
| US12295989 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11857603 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(11 years from now) | |
| US11590207 | ASCENDIS PHARMA BONE | Dosage regimen for a controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11759504 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2027 |
| New Chemical Entity Exclusivity(NCE) | Aug 09, 2029 |
| Orphan Drug Exclusivity(ODE-492) | Aug 09, 2031 |
Drugs and Companies using PALOPEGTERIPARATIDE ingredient
NCE-1 date: 09 August, 2028
Market Authorisation Date: 09 August, 2024
Dosage: SOLUTION
More Information on Dosage
YORVIPATH family patents
34. Zegalogue patent expiration
Treatment: Method of treating diabetic hypoglycemia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10442847 | ZEALAND PHARMA | Glucagon analogues |
Feb, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11795204 | ZEALAND PHARMA | Glucagon analogues |
Jan, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: 22 March, 2025
Market Authorisation Date: 22 March, 2021
Dosage: SOLUTION
More Information on Dosage
ZEGALOGUE family patents
35. Zometa patent expiration
Treatment: Hypercalcemia of malignancy
ZOMETA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4939130 (Pediatric) | NOVARTIS | Substituted alkanediphosphonic acids and pharmaceutical use |
Mar, 2013
(12 years ago) | |
| US4939130 | NOVARTIS | Substituted alkanediphosphonic acids and pharmaceutical use |
Sep, 2012
(13 years ago) | |
| US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(7 months ago) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(2 years from now) | |
|
US8324189 (Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 20, 2011 |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 20 August, 2001
Dosage: INJECTABLE
How can I launch a generic of ZOMETA before it's drug patent expiration?
More Information on Dosage
ZOMETA family patents